Safecare Biotech (Hangzhou) co., ltd





·Saliva Specimen

•Fast Result in 10 min

INTRODUCTION

The COVID-19 Antigen Rapid Test Kit (Saliva) is a lateral flow immunoassay intended for qualitative detection of nucleocapsid protein antigen in oropharyngeal saliva specimens from individuals suspected of COVID-19 by their healthcare provider within the first seven days of symptom onset.

•Easy to use

•Room temperature storage

PRODUCT PHOTOS





COMPONENT/(BOX)

25 tests packed in one Kit :

25 Test Devices

25 collection paper cups

25 Extraction bottle with buffer

25 droppers

1 Package Insert

PACKAGE SIZE / CARTON

Length:630mm

Width:370mm

Height:300mm


Weight:12.5Kgs

Include: 27 boxes/carton


675pcs/carton



Test Procedure and Interpretation



CERTIFICATE



Œ	
EC	C Declaration of Conformity
	according to the Directive 98/79/EC
(applicable	e to IVD Devices of NOT Annex II and NOT self-test)
Manufacturer:	Safecare Biotech (Hangzhou) Co., Ltd.
Address:	Building 2/203, No.18 Haishu Rd.Cangqian Sub-district,
	Yuhang District, Hangzhou, Zhejiang China 311121
EC Representative	 NIC GmbH Erlenweg 13,49076 Osnabrück,Germany
We, the manufactu	irer, declare under our sole responsibility that
the medical	Product Name COVID-19 Antigen Rapid Test Kit(Saliva)
device(s)	Type/model, identification of
	product allowing traceability COV Ag-7012 (Where applicable)
of Category:	Common/Others IVD
	(Devices of NOT Annex II and NOT self-test)
	with the relevant provisions and requirements of Directive
Medical Devices.	ropean Parliament and of the Council on In-Vitro Diagnostic
Applied harmonised	EN ISO23640:2015 EN ISO 18113-1:2011
standards, national standards or other	EN 13612:2002 ISO 18113-2: 2009
normative documents	EN 13641:2002 EN1041- 2016 EN ISO 14971:2019 EN ISO15223-1:2016
	ISO13485:2016
Conformity	
procedure	Module A (EC Declaration of Conformity) (Annex III, except point 6)
Notified Body	NOT applicable
(name & number) Certificate & number	
Signed on 3th Feb.,202	Place: Hangzhou, Zhejiang, Chinath - 1
	the manufacturer
Signature (on behalf of	the manufacturer)
Name of authorized sig	natory: Kebin, Qiu 🛛 🔆 🏹 🥹
Position held in the cor	npany: General Manager
Seal/Stamp:	3301100115
a total	

Anlage 2 (zu § 4 Abs. 1 Nr. 1 DIMDIV) Formularnummer 0016 1080

Allgemeine Anzeigepflicht nach §§ 25 und 30 Abs. 2 MPG General Obligation to Notify pursuant to §§ 25 and 30 (2) Medical Devices Act, MPG

Formblatt für In-vitro-Diagnostika / Form for In Vitro Diagnostic Medical Devices

Code DE/CA11	
Bezeichnung / Name Staatliches Gewerbeaufsichtsamt Oldenburg	7
Staat / State Deuts chland	Land / Federal state Nieders achsen
Ort / City Oldenburg	Postleitzahl / Postal code 26122
Straße, Haus-Nr. / Street, house no. Theodor-Tantzen-Platz 8	
Telefon / Phone +49-441-7990	Telefax / Fax +49-441-7992700
E-Mail / E-mail poststelle@gaa-ol.niedersachsen.de	
zeige / Notification	
Registrierdatum bei der zuständigen Behörde Registration date at competent authority 18.02.2021	Registriemummer / Registration number DE/CA11/923-4341
Typ der Anzeige / Notification type	
Erstanzeige / Initial notification	
Änderungsanzeige / Notification of change	
Widerrufsanzeige / Notification of withdrawal	
Frühere Registriemummer bei Änderungs- und Wide Previous registration number if notification has been	
Anzeigender nach § 25 MPG / Reporter pursuant to	§ 25 Medical Devices Act, MPG
Hersteller / Manufacturer	
Bevollmächtigter / Authorised Representative	
Einführer / Importer	
Verantwortlicher f ür das Zusammensetzen von Sy	stemen oder Behandlungseinheiten nach § 10 Abs. 1 und 2
MPG \ Assembler of systems or procedure packs put	rsuant to § 10 (1) and (2) Medical Devices Act, MPG
Betrieb oder Einrichtung (aufbereiten) nach § 25 A	bs. 1 MPG i. V. m. § 4 Abs. 2 MPBetreibV
Institution (processing) pursuant to § 25 (1) Medic	al Devices Act, MPG in connection with § 4 (2) MPBetreib
Betrieb oder Einrichtung (sterilisieren) nach § 25 A	vbs. 2 i. V. m. § 10 Abs. 3 MPG
Institution (sterilizing) pursuant to § 25 (2) in conn	ection with § 10 (3) Medical Devices Act, MPG



国家食品药品监督管理总局制

ADVANTAGE

1. Easy to collect samples simple operation without professional equipment.

2.The test results are available in 10 minutes, and the test results are clearly visible.

3.Convenient transportation and low price, higher accuracy.

4.Suitable for large-scale rapid screening.





Safecare Biotech (Hangzhou) Co.,Ltd.

Clinical Evaluation Report

1 Purpose:

In order to verify the clinical performance of the improved test

2 Material:

Fresh negative COVID-19 samples were collected from the hospital and validated by PCR.

Fresh positive COVID-19 samples were collected from CDC and validated by PCR. Product used: COV20101001

3 Protocol:

1) Sample Size:

Positive Sample: >100 Negative Sample:>100

2) Sample's collection:

loropharyngeal saliva and 1 oropharyngeal swab were collected at the same time from each patient. The oropharyngeal saliva was tested directly with Safecare COVID-19 Ag Card test kit according to product instructions. The oropharyngeal swab was eluted in viral transport media (VTM). All samples were randomly blinded and assigned to testing with PCR assay as the comparator method for this study.

3) Sample Entry criteria:

The samples from hospital outpatient screening cases and COVID-19 Patients who presented within 7 days of symptom onset; Samples of people that gender and age are not limited.

4) Sample Exclusion criteria:

Samples without PCR test results; Samples that the quantity is not enough to complete the test; Samples with failed test results (C-line has not appeared); Freeze samples repeatedly.

5) Comparator method

All samples was confirmed by RT-PCR, Novel Coronavirus (2019-nCoV) Nucleia Acid Diagnostic Kit (PCR-Fluorescence Probing) manufactured by Sansure BioTech Inc. PCR tests performed on AB17500.

4 Operator and site: Site 1: CDC-Immunology Laboratory

Safecare Biotech (Hangzhou) Co.,Ltd.

Researcher: Dr. ZHANG LEI Site 2: Hospital- Immunology Laboratory Researcher: Dr.Xuwei

5 Statistical methods:

1) Statistical of test result

		Referencing reagent Test		Total
		Positive Negative	Ioai	
Research Reagent	Positive	Α	В	A+B
	Negative	С	D	C+D
Total		A+C	B+D	A+B+C+D

Positive Percent Agreement=A/(A+C)*100% Negative Percent Agreement=D/(B+D)*100% Overall Agreement=(A+D)/(A+B+C+D)*100%

2) Statistical of Specimens correlation

Record and statistics the correlation of antigen-positive/PCR-positive and antigen-negative/ PCR-positive samples with the Ct values of the PCR to determine the mean Ct value of antigen-positive samples

6 Evaluation indicators:

The total PPA should be no less than 95%. The total NPA should be no less than 95%.

7 Statistical results of the clinical evaluation

1) Test result

		Referencing Method (RT-PCR)		Total
		Positive Negative		
lest-strip	Positive	131	1	132
	Negative	2	182	184
To	stal	133	183	

Project	Value	Percentage (95% confidence interval)
Relative Sensitivity-PPA (%)	131/133	98.50% (94.67%~99.82%)
Relative Specificity-NPA (%)	182/183	99.45% (96.99%-99.99%)
Overall Agreement (%)	313/316	99.05% (97.25%~99.80%)

2) Kappa consistency test

Calculate the Kappa value and standard error; test hypothesis is established for Kappa: H0: k = 0, Kappa value comes from 0 population, H1: k > 0, Kappa value comes from non-0 population, $\alpha = 0.05$.

1 SAFECARE BO-TECH Safecare Biotech (Hangzhou) Co.,Ltd. Project Value Kappa Value 0.9805, Good consistency, Standard Error Se(K) 0.0112 95% Confidence Interval 0.9585~1.0025 Standard Error Se0(K) 0.056 Z=17.4302 Probability value P=0.0000 Test Value Z Test Result P<0.05, refuse H0, Kappa values come from populations other than 0.

3) Specimens correlation

The performance of Safecare COVID-19 Antigen Rapid Test Kit(Saliva) with positive results stratified by the comparator method (Ct) counts were collected and assessed to determine the correlation of assay performance to the Ct.

Safecare COVID-19	Comparator Method (POS by Ct ≤ 40)		
Antigen Rapid Test	Ct<30	Ct≥30	
Positive	128	3	
Negative	0	2	
Total	128	5	
Positive Agreement(95% CI)	100.00% (97.16%~100.00%)	60.00% (0.51%~71.64%)	

Based on above table, the positive agreement of the Safecare COVID-19 Antigen Rapid TestKit(Swab) is higher with samples of a Ct count <30.

8 Conclusion


 A side-by-side comparison was conducted using the research reagent and referencing reagent. Compare with RT-PCR:

The Relative Sensitivity is 98.50%, the Relative Specificity is 99.45%, the Overall Agreement is 99.05%.

In summary, The study showed that there is a high coincidence rate between the test-strip and RT-PCR, and have the equivalence on the clinical usage.

Reporter: Wu Gang Date: 2021.01.25

Safecare Biotech (Hangzhou) Co.,Ltd



COMPANY PROFILE

Safecare Biotech(Hangzhou)Co.,Ltd. is a premier and professional manufacturer and supplier of rapid diagnostic test kit with 165 workers, 8000 m² non-dust workshop, a professional R&D team who has 15 years experience in rapid test field, advanced automate machines and professional R&D team ensure the high quality, speedy delivery and large production capacity. SAFECARE earned the reputation as a premium brand known for exceptional quality, consistency and innovation.

Our product ranges drug of abuse and alcohol test in urine and saliva, Food Safety test, Women Health test, Infectious Diseases test, Cardiac Markers test and Tumor Markers test with CE & ISO approved. Our drugs tests are even US FDA 510K and CLIA Waived approved which can ensure you high and stable quality.

The available rapid test kits are designed for health-care professionals in laboratories, rehabilitation centers, treatment centers, hospitals, clinics, private practices, human resource departments, mining companies, construction companies and the judicial system. All the products are produced strictly under TUV ISO13485:2016 quality management system for medical devices.

With our highly trained staffs and good service, we are committed to provide professional service and a comprehensive, cutting-edge product offering, help you in selecting the accurate and fast rapid tests and to provide the free samples for your evaluation.